The historical rank and industry rank for Cannara Biotech's FCF Margin % or its related term are showing as below:
TSX:LOVE'
s FCF Margin % Range Over the Past 10 Years
Min: -1464.14 Med: -60.12 Max: 14.28
Current: 14.28
During the past 8 years, the highest FCF Margin % of Cannara Biotech was 14.28%. The lowest was -1464.14%. And the median was -60.12%.
TSX:LOVE's FCF Margin % is ranked better than 79.96% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs TSX:LOVE: 14.28
Cannara Biotech FCF Margin % Related Terms
Cannara Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (TSX:LOVE) has a FCF Margin % of -1.06% as of Feb. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cannara Biotech and its competitors. According to the industry distribution chart, Cannara Biotech ranks #192 out of 958 companies in the Drug Manufacturers industry, placing it in the top 20%.
Is Cannara Biotech's FCF Margin % too high?
Cannara Biotech's current FCF Margin % is -1.06%. Based on the distribution chart, Cannara Biotech ranks #192 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cannara Biotech has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #192 out of 958 companies for FCF Margin %. This places Cannara Biotech in the top 20% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current FCF Margin % is -1.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (TSX:LOVE) is currently considered Fairly Valued. The stock's GF Value™ is C$1.68, compared to a current price of C$1.68 — trading right at its estimated fair value. The current FCF Margin % is -1.06%. Cannara Biotech's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cannara Biotech (TSX:LOVE), the current FCF Margin % is -1.06% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (TSX:LOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued.
The current stock price of C$1.68 is trading 0% below its estimated GF Value™ of C$1.68.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for TSX:LOVE:
FCF Margin %: -1.06%
GF Value™: C$1.68 vs. price of C$1.68 (0% below fair value)
No single metric tells the full story. See the TSX:LOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
92GF Score
Get the complete analysis for TSX:LOVE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LOVE has been successfully added to your 
